Friday, 31 October, 2025
London, UK
Friday, October 31, 2025 3:30 PM
broken clouds 15.8°C
Condition: Broken clouds
Humidity: 83%
Wind Speed: 24.1 km/h

FDA recalls blood pressure medicine tainted with cancer-causing chemical

The U.S. Food and Drug Administration says drug makers have recalled more than a half-million bottles of the blood pressure medication prazosin hydrochloride over concerns it may include a cancer-causing chemical.

New Jersey-based Teva Pharmaceuticals USA and drugs distributor Amerisource Health Services issued voluntary nationwide recalls earlier this month of more than 580,000 bottles of various strengths of prazosine capsules, according to the FDA.

Doctors prescribe prazosin, which relaxes blood vessels, to help lower blood pressure. It also is sometimes prescribed for nightmares and other sleep disturbances caused by post-traumatic stress disorder.

The FDA said in enforcement orders posted online that it has given the affected lots of the drug a Class II risk classification because some of the recalled medication may have nitrosamine impurities that are considered potentially cancer causing.

According to the FDA, N-nitrosamine impurities are a class of potentially cancer-causing chemicals that can form during manufacture or storage of a drug.

LP Staff Writers

Writers at Lord’s Press come from a range of professional backgrounds, including history, diplomacy, heraldry, and public administration. Many publish anonymously or under initials—a practice that reflects the publication’s long-standing emphasis on discretion and editorial objectivity. While they bring expertise in European nobility, protocol, and archival research, their role is not to opine, but to document. Their focus remains on accuracy, historical integrity, and the preservation of events and individuals whose significance might otherwise go unrecorded.

Categories

Follow

    Newsletter

    Subscribe to receive your complimentary login credentials and unlock full access to all features and stories from Lord’s Press.

    As a journal of record, Lord’s Press remains freely accessible—thanks to the enduring support of our distinguished partners and patrons. Subscribing ensures uninterrupted access to our archives, special reports, and exclusive notices.

    LP is free thanks to our Sponsors

    Privacy Overview

    Privacy & Cookie Notice

    This website uses cookies to enhance your browsing experience and to help us understand how our content is accessed and used. Cookies are small text files stored in your browser that allow us to recognise your device upon return, retain your preferences, and gather anonymised usage statistics to improve site performance.

    Under EU General Data Protection Regulation (GDPR), we process this data based on your consent. You will be prompted to accept or customise your cookie preferences when you first visit our site.

    You may adjust or withdraw your consent at any time via the cookie settings link in the website footer. For more information on how we handle your data, please refer to our full Privacy Policy